Every 10-Q that Omeros Corporation (OMER) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OMER and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OMER filings page.
Omeros Corporation reported its first commercial quarter for YARTEMLEA, generating $28.5 million in product sales for the quarter and $38.4 million for the first half of 2026, compared with no product sales in 2025. Net income for the quarter was $13.2 million and for the first six months $69.3 million, versus net losses of $25.4 million and $58.9 million in the prior‑year periods, helped by a $84.6 million net gain on changes in fair value of financial instruments and income from discontinued OMIDRIA royalties.
Cash and cash equivalents were $2.0 million with $130.0 million in short‑term investments as of June 30, 2026. Net cash used in operating activities was $10.4 million for the first half. The OMIDRIA contract royalty asset totaled $116.5 million, offset by an OMIDRIA royalty obligation of $157.9 million. Omeros repurchased portions of its 2029 convertible notes, leaving $54.8 million principal outstanding, and shareholders’ deficit narrowed to $51.3 million from $121.2 million at year‑end 2025.
Omeros Corporation reported a sharp turnaround in Q1 2026, posting net income of $56.1 million versus a $33.5 million loss a year earlier. The improvement was largely due to a $73.1 million non-cash gain from remeasuring the embedded derivative on its 2029 convertible notes.
Product sales reached $9.9 million following the January 2026 U.S. launch of YARTEMLEA for TA-TMA, while research and development spending declined to $13.4 million from $23.8 million. Operating cash flow remained negative at $14.5 million, but Omeros held $1.9 million in cash and $133.4 million in short-term investments as of March 31, 2026.
The balance sheet shows a shareholders’ deficit of $63.3 million, improved from $121.2 million at year-end 2025, influenced by the zaltenibart sale and debt actions. The company also continues to recognize income from OMIDRIA royalties and retains significant potential milestones and royalties from its APLA with Novo Nordisk.
Omeros Corporation reported a wider third‑quarter net loss while managing liquidity and advancing key transactions. For Q3 2025, net loss was $30.9 million, including a $21.2 million loss from continuing operations and a $9.7 million loss from discontinued operations. Operating costs eased year over year, with R&D $16.0 million (down from $24.1 million) and SG&A $10.4 million (down from $11.3 million).
As of September 30, 2025, cash, cash equivalents, and short‑term investments totaled $36.1 million, and cash used in operations for the nine months was $76.3 million. Shareholders’ deficit was $220.5 million. The company disclosed substantial doubt about its ability to continue as a going concern absent additional financing, asset sales, or closing its pending transaction.
On October 10, 2025, Omeros signed an Asset Purchase and License Agreement with Novo Nordisk, eligible for $340.0 million in upfront and near‑term payments, including $240.0 million at closing, plus up to $410.0 million in development/approval milestones, up to $1.3 billion in sales milestones, and tiered royalties. The transaction is expected to close in Q4 2025. The FDA target action date for narsoplimab in TA‑TMA was extended to December 26, 2025; an EU opinion is expected mid‑2026.